Adjuvant ET, which includes TAM, a selective estrogen receptor modulator, or AIs, is another variable in the multimodal treatment of early-stage HR+ breast cancer with the opportunity to explore de-escalation in select patients. The gene discussed is ESR1; the disease is breast carcinoma.